S

Synaptogenix
D

SNPX

4.26000
USD
0.52
(13.90%)
مغلق
حجم التداول
0
الربح لكل سهم
-9
العائد الربحي
-
P/E
-0
حجم السوق
5,920,612
أصول ذات صلة
AMAT
AMAT
5.910
(3.46%)
176.530 USD
AMD
AMD
10.220
(8.80%)
126.400 USD
ASML
ASML
14.13
(1.86%)
775.24 USD
AVGO
AVGO
3.330
(1.34%)
252.130 USD
INTC
INTC
0.575
(2.85%)
20.730 USD
KLAC
KLAC
24.82
(2.86%)
892.49 USD
LRCX
LRCX
3.890
(4.34%)
93.420 USD
M
MTSI
2.260
(1.75%)
131.240 USD
MU
MU
4.200
(3.63%)
119.810 USD
NVDA
NVDA
2.740
(1.93%)
144.680 USD
TER
TER
4.600
(5.54%)
87.700 USD
المزيد
الأخبار المقالات

العنوان: Synaptogenix

القطاع: Healthcare
الصناعة: Biotechnology
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment ofAlzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.